$11.7 M

MDIT Mkt cap, 28-Sep-2018

$2.4 M

Medite Cancer Diagnostics Revenue Q3, 2018
Medite Cancer Diagnostics Gross profit (Q3, 2018)1.5 M
Medite Cancer Diagnostics Gross profit margin (Q3, 2018), %61.4%
Medite Cancer Diagnostics Net income (Q3, 2018)-735 K
Medite Cancer Diagnostics EBIT (Q3, 2018)-95 K
Medite Cancer Diagnostics Cash, 30-Sep-201890 K
Medite Cancer Diagnostics EV17.4 M

Medite Cancer Diagnostics Revenue

Medite Cancer Diagnostics revenue was $6.81 m in FY, 2017

Embed Graph

Medite Cancer Diagnostics Income Statement

Annual

USDFY, 2013FY, 2015FY, 2016FY, 2017

Revenue

24.0k9.9m9.2m6.8m

Revenue growth, %

(7%)

Cost of goods sold

8.0k6.1m5.6m6.7m

Gross profit

16.0k3.8m3.6m162.0k

Gross profit Margin, %

67%38%39%2%

R&D expense

250.0k1.3m1.5m1.2m

General and administrative expense

584.0k2.9m3.6m5.2m

Operating expense total

834.0k4.2m5.1m6.6m

EBIT

(818.0k)(599.0k)(1.7m)(6.5m)

EBIT margin, %

(3408%)(6%)(18%)(95%)

Interest expense

8.0k204.0k694.0k849.0k

Pre tax profit

(781.0k)(7.3m)

Income tax expense

78.0k(132.0k)(487.0k)

Net Income

(923.0k)(859.0k)(2.2m)(6.8m)

Medite Cancer Diagnostics Balance Sheet

Annual

USDFY, 2013FY, 2015FY, 2016FY, 2017

Cash

1.0k587.0k108.0k73.0k

Accounts Receivable

10.0k66.7m

Inventories

5.0k3.1m3.8m2.4m

Current Assets

16.0k5.6m5.3m3.5m

PP&E

5.0k1.9m1.6m1.8m

Goodwill

4.7m4.7m4.7m

Total Assets

21.0k18.4m17.8m16.0m

Accounts Payable

85.7m3.3m

Short-term debt

36.0k

Current Liabilities

4.3m6.2m7.3m3.8m

Long-term debt

36.0k4.9m

Total Debt

72.0k4.9m

Total Liabilities

9.7m10.2m

Additional Paid-in Capital

97.1m8.3m9.4m13.8m

Retained Earnings

(102.8m)779.0k(1.4m)(8.2m)

Total Equity

(4.3m)9.2m8.0m5.8m

Debt to Equity Ratio

0 x0.8 x

Debt to Assets Ratio

3.4 x0.3 x

Financial Leverage

0 x2 x2.2 x2.8 x

Medite Cancer Diagnostics Cash Flow

Annual

USDFY, 2013FY, 2015FY, 2016FY, 2017

Net Income

(923.0k)(859.0k)(2.2m)(6.8m)

Depreciation and Amortization

74.0k177.0k214.0k293.0k

Accounts Receivable

123.0k314.0k589.0k

Inventories

6.0k340.0k(841.0k)1.4m

Accounts Payable

(94.0k)(285.0k)557.0k(75.0k)

Cash From Operating Activities

(498.0k)(388.0k)(1.1m)(3.6m)

Purchases of PP&E

(208.0k)(115.0k)

Cash From Investing Activities

(354.0k)(115.0k)(134.0k)

Cash From Financing Activities

460.0k1.7m700.0k3.5m

Interest Paid

197.0k179.0k225.0k

Income Taxes Paid

77.0k8.0k

Medite Cancer Diagnostics Ratios

USDY, 2018

EV/EBIT

-182.9 x

EV/CFO

-5 x

Financial Leverage

2.7 x